Beyond point mutations detected by Ames testing lies another universe of genetic damage - chromosome-level changes including deletions, translocations, and recombinations that cause cancer yet bacterial tests cannot detect, demanding mammalian cell assays that capture the full spectrum of genotoxic mechanisms. The Mouse Lymphoma Assay represents the most comprehensive in vitro genotoxicity test, simultaneously detecting both gene mutations and chromosomal damage in mammalian cells following ISO 10993-3 Method C (FDA) and OECD TG490, providing critical safety data for medical devices where genetic damage poses long-term cancer risks. This sophisticated assay exposes L5178Y mouse lymphoma cells to device extracts prepared in both polar and non-polar solvents, measuring forward mutation frequency at the thymidine kinase locus while colony sizing distinguishes between point mutations producing large colonies and chromosomal damage generating small colonies indicating clastogenic effects. Regulatory authorities increasingly require Mouse Lymphoma testing for long-term implantable devices exceeding 30 days contact, devices with positive or equivocal Ames results requiring mammalian cell confirmation, and novel materials where comprehensive genotoxicity assessment proves essential for risk characterization. The limit study design tests maximum feasible concentrations ensuring that negative results genuinely indicate safety rather than insufficient exposure, with GLP compliance providing pharmaceutical-grade data quality that regulatory submissions demand for pivotal safety studies supporting premarket approvals. Critical for implantable devices where chronic material exposure creates cumulative cancer risk requiring demonstration that materials don't cause genetic damage through extended contact, cardiovascular devices where genotoxicity could initiate malignancies in critical tissues, and orthopedic implants with decades-long patient exposure demanding comprehensive genetic safety assessment. The dual assessment of mutagenicity and clastogenicity provides complete genotoxicity profiling in single assay, revealing whether materials cause point mutations affecting individual genes or chromosomal damage impacting multiple genes simultaneously, both mechanisms contributing to cancer development through different pathways.